10x Science Secures $4.8M Seed to Scale AI-Driven Protein Characterization for Drug Development

New updates have been reported about 10x Science.

10x Science has closed a $4.8 million seed round led by Initialized Capital, with participation from Y Combinator, Civilization Ventures, Founder Factor, and strategic angels, to accelerate its AI-native platform for molecular-level protein characterization. The San Francisco Bay Area company targets a core bottleneck in biologic drug development by replacing months of expert-driven mass spectrometry interpretation with automated, explainable analyses delivered in minutes.

Founded in December 2025 by David Stephen Roberts, Ph.D., Andrew Reiter, and Vishnu Tejus out of Nobel laureate Carolyn Bertozzi’s Stanford lab, 10x Science is building purpose-built AI models that learn across hundreds of thousands of spectra and retain deep memory of each customer’s molecular portfolio. The platform focuses on the characterization layer of drug development, where regulatory-grade data underpin decisions and FDA filings, positioning 10x Science as infrastructure for the fast-growing biologics segment and as a potential shared intelligence layer across pharma, biotech, and research institutions.

Roberts, a Damon Runyon Cancer Research Fellow with more than 38 publications, contributed much of the underlying science for next-generation protein characterization, while Reiter brings experience from the Broad Institute in building analytical tools that map how drugs bind their targets. Tejus, a two-time Y Combinator founder, complements this with company-building expertise, and together the team aims to bridge the long-standing gap between cutting-edge AI and life science workflows that remain largely manual. As pharma advances increasingly complex therapeutics and generates expanding volumes of experimental data, 10x Science’s explainable AI is designed to scale with rising regulatory scrutiny and to aggregate molecular insight across programs.

Industry backers highlight that biologics are the fastest-growing and most complex segment of the pharmaceutical market, and that existing characterization tools have not kept pace with the volume and sophistication of new therapies. By enabling AI-driven interpretation of real experimental data rather than just structural predictions, 10x Science is targeting a high-value, non-discretionary step that recurs throughout the drug lifecycle regardless of any single asset’s success. With the new capital, the company is hiring founding engineers and deepening collaborations with pharmaceutical and biotech partners, aiming to create a foundational “molecular intelligence” layer with applications spanning oncology, neurodegeneration, infectious disease, agriculture, and basic research.

Management frames the long-term vision as building a shared, continuously learning system that can detect patterns across thousands of characterized therapeutics, distinguishing drugs that succeed from those that fail at a molecular level. Every analysis is designed to be traceable and auditable to meet regulatory expectations, in contrast to legacy tools that start from zero for each dataset and operate largely as point solutions. If 10x Science succeeds in scaling its platform across organizations, it could become a critical decision-support and infrastructure provider for the life sciences, with implications for R&D efficiency, regulatory strategy, and the economics of complex biologic pipelines.